Skip to content

A study to compare the effectiveness of combined hyaluronic acid mouthrinse with chlorhexidine and chlorhexidine mouthrinse alone on clinical parameters along with salivary aspartate marker level in Periodontitis patients after scaling and root planing

Effectiveness of 0.1 percent Hyaluronic Acid with 0.2 percent Chlorhexidine Mouthrinse or 0.2 percent Chlorhexidine Mouthrinse alone as adjunct to scaling and root planing on clinical parameters and salivary aspartate aminotransferase marker in Periodontitis : A Prospective randomized observer blinded study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/077456
Enrollment
50
Registered
2024-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Clohexidine with hyaluronic acid mouthrinse: Clohex-Heal 26/1/Aushadhi/53/2019/19404 10ml for 60 sec BD, For 2 months Control Intervention1: Chlorhexidine Digluconate Mouthrinse: Clohex

Sponsors

Dr Saveen Mohod
Lead Sponsor
Dr Reddys Laboratories Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects aged 18-60 years rendering informed consent. 2.Presence of minimum 20 natural scorable teeth excluding third molars. 3.Subiects diagnosed with Periodontitis based according to 2017 International Workshop for classification of Periodontal Diseases and Conditions of the American Academy of Periodontology 4.Presence of at least 4 sites in different quadrants with a Probing depth of =5mm. 5.Subjects having good level of oral hygiene (a mean plaque index PI) score = 1).

Exclusion criteria

Exclusion criteria: 1.Subjects who have received any form of periodontal therapy, surgical or nonsurgical within past 6 months. 2.Subjects who have received antibiotic and/or anti-inflammatory therapy within the past 3 months. 3.Subjects wearing orthodontic appliances. 4.Subjects suffering from any systemic diseases like (Diabetes mellitus, cardiovascular diseases like ischemic heart disease, cerebrovascular diseases, and peripheral vascular disease, osteoporosis, rheumatoid arthritis, respiratory diseases like COPD) 5.Subjects who give present or past history of drug abuse. 6.Subjects who give present or past history of smoking and tobacco consumption. 7.Pregnant women (Preterm/low birth weight babies) and lactating mothers.

Design outcomes

Primary

MeasureTime frame
Clinical attachment level and Probing pocket depthTimepoint: Baseline, 4 weeks and 8 weeks

Secondary

MeasureTime frame
Salivary aspartate aminotransferase markerTimepoint: Baseline, 4 weeks and 8 weeks

Countries

India

Contacts

Public ContactDr Saveen Mohod

Mgm Dental College and Hospital Navi Mumbai

shettysarika98@gmail.com9820007410

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026